American Journal of Kidney Diseases
Volume 56, Issue 3 , Pages 578-584 , September 2010

A Physiologic-Based Approach to the Treatment of Acute Hyperkalemia

  • Roman Shingarev, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Roman Shingarev, MD, University of Alabama at Birmingham, ZRB 624, 1530 3rd Ave S, Birmingham, AL 35294
    • ,
  • Michael Allon, MD

Received 30 November 2009 ,Accepted 4 March 2010.

References 

  1. Palmer BF. A physiologic-based approach to the evaluation of a patient with hyperkalemia [published online ahead of print 2010]. Am J Kidney Dis. doi:10.1053/j.ajkd.2010.01.020.
  2. Schaefer TJ, Wolford RW. Disorders of potassium. Emerg Med Clin North Am. 2005;23(3):723–747
  3. Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders. 5th ed.. New York, NY: McGraw-Hill; 2001;
  4. Bia MJ, Lu D, Tyler K, De Fronzo RA. Beta adrenergic control of extrarenal potassium disposal: a beta-2 mediated phenomenon. Nephron. 1986;43(2):117–122
  5. Clausen T, Hansen O. Active Na-K transport and the rate of ouabain binding: the effect of insulin and other stimuli on skeletal muscle and adipocytes. J Physiol. 1977;270(2):415–430
  6. Velázquez H, Perazella MA, Wright FS, Ellison DH. Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med. 1993;119(4):296–301
  7. Bonilla S, Goecke IA, Bozzo S, Alvo M, Michea L, Marusic ET. Effect of chronic renal failure on Na,K-ATPase alpha 1 and alpha 2 mRNA transcription in rat skeletal muscle. J Clin Invest. 1991;88(6):2137–2141
  8. Pratt JH. Role of angiotensin II in potassium-mediated stimulation of aldosterone secretion in the dog. J Clin Invest. 1982;70(3):667–672
  9. Smellie WS. Spurious hyperkalaemia. BMJ. 2007;334(7595):693–695
  10. Rabelink TJ, Koomans HA, Hene RJ, Dorhout Mees EJ. Early and late adjustment to potassium loading in humans. Kidney Int. 1990;38(5):942–947
  11. Montague BT, Ouellette JR, Buller GK. Retrospective review of the frequency of ECG changes in hyperkalemia. Clin J Am Soc Nephrol. 2008;3(2):324–330
  12. Diercks DB, Shumaik GM, Harrigan RA, Brady WJ, Chan TC. Electrocardiographic manifestations: electrolyte abnormalities. J Emerg Med. 2004;27(2):153–160
  13. Webster A, Brady W, Morris F. Recognising signs of danger: EKG changes resulting from an abnormal serum potassium concentration. Emerg Med J. 2002;19(1):74–77
  14. Bisogno JL, Langley A, Von Dreele MM. Effect of calcium to reverse the electrocardiographic effects of hyperkalemia in the isolated rat heart: a prospective, dose-response study. Crit Care Med. 1994;22(4):697–704
  15. Weisberg LS. Management of severe hyperkalemia. Crit Care Med. 2008;36(12):3246–3251
  16. Allon M, Takeshian A, Shanklin N. Effect of insulin-plus-glucose infusion with or without epinephrine on fasting hyperkalemia. Kidney Int. 1993;43(1):212–217
  17. Allon M, Copkney C. Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients. Kidney Int. 1990;38(5):869–872
  18. Montoliu J, Lens XM, Revert L. Potassium-lowering effect of albuterol for hyperkalemia in renal failure. Arch Intern Med. 1987;147(4):713–717
  19. Sowinski KM, Cronin D, Mueller BA, Kraus MA. Subcutaneous terbutaline use in CKD to reduce potassium concentrations. Am J Kidney Dis. 2005;45(6):1040–1045
  20. Gutierrez R, Schlessinger F, Oster JR, Rietberg B, Perez GO. Effect of hypertonic versus isotonic sodium bicarbonate on plasma potassium concentration in patients with end-stage renal-disease. Miner Electrolyte Metab. 1991;17(5):297–302
  21. Allon M, Shanklin N. Effect of bicarbonate administration on plasma potassium in dialysis patients: interactions with insulin and albuterol. Am J Kidney Dis. 1996;28(4):508–514
  22. Kim HJ. Combined effect of bicarbonate and insulin with glucose in acute therapy of hyperkalemia in end-stage renal disease patients. Nephron. 1996;72(3):476–482
  23. Carlisle EJ, Donnelly SM, Ethier JH, et al. Modulation of the secretion of potassium by accompanying anions in humans. Kidney Int. 1991;39(6):1206–1212
  24. Frohnert PP, Johnson WJ, Mueller GJ, Tauxe WN, McCall JT. Resin treatment of hyperkalemia (I. Exchange properties of a cation exchange resin (calcium cycle)). J Lab Clin Med. 1968;71(5):834–839
  25. Emmett M, Hootkins RE, Fine KD, Santa Ana CA, Porter JL, Fordtran JS. Effect of three laxatives and a cation exchange resin on fecal sodium and potassium excretion. Gastroenterology. 1995;108(3):752–760
  26. US Food and Drug Administration. Kayexalate (sodium polystyrene sulfonate) powder. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm186845.htmAccessed January 10, 2010
  27. Alfonzo A, Isles C, Geddes C, Deighan C. Potassium disorders—clinical spectrum and emergency management. Resuscitation. 2006;70(1):10–25
  28. Ahmed J, Weisberg LS. Hyperkalemia in dialysis patients. Semin Dial. 2001;14(5):348–356
  29. Putcha N, Allon M. Management of hyperkalemia in dialysis patients. Semin Dial. 2007;20(5):431–439

 Originally published online as doi:10.1053/j.ajkd.2010.03.014 on June 7, 2010.

PII: S0272-6386(10)00688-8

doi: 10.1053/j.ajkd.2010.03.014

American Journal of Kidney Diseases
Volume 56, Issue 3 , Pages 578-584 , September 2010

Article Tools

* Image Usage & Resolution